izpis_h1_title_alt

Synthesis and biochemical evaluation of warhead-decorated psoralens as (immuno)proteasome inhibitors
ID Shannon Schiffrer, Eva (Author), ID Proj, Matic (Author), ID Gobec, Martina (Author), ID Rejc, Luka (Author), ID Šterman, Andrej (Author), ID Mravljak, Janez (Author), ID Gobec, Stanislav (Author), ID Sosič, Izidor (Author)

.pdfPDF - Presentation file, Download (3,29 MB)
MD5: F407D2A35BAAEE235946E9354770162A
URLURL - Source URL, Visit https://www.mdpi.com/1420-3049/26/2/356 This link opens in a new window

Abstract
The immunoproteasome is a multicatalytic protease that is predominantly expressed in cells of hematopoietic origin. Its elevated expression has been associated with autoimmune diseases, various types of cancer, and inflammatory diseases. Selective inhibition of its catalytic activities is therefore a viable approach for the treatment of these diseases. However, the development of immunoproteasome-selective inhibitors with non-peptidic scaffolds remains a challenging task. We previously reported 7H-furo[3,2-g]chromen-7-one (psoralen)-based compounds with an oxathiazolone warhead as selective inhibitors of the chymotrypsin-like (β5i) subunit of immunoproteasome. Here, we describe the influence of the electrophilic warhead variations at position 3 of the psoralen core on the inhibitory potencies. Despite mapping the chemical space with different warheads, all compounds showed decreased inhibition of the β5i subunit of immunoproteasome in comparison to the parent oxathiazolone-based compound. Although suboptimal, these results provide crucial information about structure–activity relationships that will serve as guidance for the further design of (immuno)proteasome inhibitors.

Language:English
Keywords:immunoproteasome, psoralen core, non-peptidic, electrophilic compounds, warhead scan
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:18 str.
Numbering:Vol. 26, iss. 2, art. 356
PID:20.500.12556/RUL-134920 This link opens in a new window
UDC:615.4:54:616-097
ISSN on article:1420-3049
DOI:10.3390/molecules26020356 This link opens in a new window
COBISS.SI-ID:46540803 This link opens in a new window
Publication date in RUL:11.02.2022
Views:741
Downloads:125
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Molecules
Shortened title:Molecules
Publisher:MDPI
ISSN:1420-3049
COBISS.SI-ID:18462981 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:12.01.2021

Secondary language

Language:Slovenian
Keywords:imunopreoteasom, zaviralci, psoralen, avtoimunske bolezni, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:N1-0068
Name:Identifikacija nepeptidnih inhibitorjev imunoproteasoma z metodami razvoja učinkovin na osnovi fragmentov

Funder:ARRS - Slovenian Research Agency
Project number:J3-1745
Name:Vloga imunoproteasoma v oblikovanju imunskega odziva, posredovanega s trombociti

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back